Amodio Donato, Manno Emma Concetta, Cotugno Nicola, Santilli Veronica, Franceschini Alessio, Perrone Marco Alfonso, Chinali Marcello, Drago Fabrizio, Cantarutti Nicoletta, Curione Davide, Engler Renata, Secinaro Aurelio, Palma Paolo
Clinical and Research Unit of Clinical Immunology and Vaccinology, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Chair of Pediatrics, Department of Systems Medicine, University of Rome "Tor Vergata", Rome, Italy.
Vaccine X. 2023 Aug;14:100318. doi: 10.1016/j.jvacx.2023.100318. Epub 2023 May 27.
Whilst there has been significant public health benefits associated with global use of COVID-19 spike protein vaccines, potential serious adverse events following immunization have been reported. Acute myocarditis is a rare complication of COVID19 vaccines and often it is self-limiting. We describe two cases experiencing recurrent myocarditis following mRNA COVID-19 vaccine despite a prior episode with full clinical recovery. Between September 2021-September 2022 we observed two male adolescents with recurrent myocarditis related to mRNA-based-COVID19 vaccine. During the first episode both patients presented with fever and chest pain few days after their second dose of BNT162b2 mRNA Covid-19 Vaccine (Comirnaty®). The blood exams showed increased cardiac enzymes. In addition, complete viral panel was run, showing HHV7 positivity in a single case. The left ventricular ejection fraction (LVEF) was normal at echocardiogram but cardiac magnetic resonance scanning (CMR) was consistent with myocarditis. They were treated with supportive treatment with full recovery. The 6 months follow-up demonstrated good clinical conditions with normal cardiological findings. The CMR showed persistent lesions in left ventricle 's wall with LGE. After some months the patients presented at emergency department with fever and chest pain and increased cardiac enzymes. No decreased LVEF was observed. The CMR showed new focal areas of edema in the first case report and stable lesions in the second one. They reached full recovery with normalization of cardiac enzymes after few days. These case reports outline the need of strict follow-up in patients with CMR consistent with myocarditis after mRNA-based-COVID19 vaccine. More efforts are necessary to depict the underlying mechanisms of myocarditis after SARS-CoV2 vaccination to understand the risk of relapsing and the long-term sequelae.
虽然全球使用新冠病毒刺突蛋白疫苗带来了显著的公共卫生益处,但也有免疫接种后出现潜在严重不良事件的报告。急性心肌炎是新冠病毒疫苗罕见的并发症,通常为自限性。我们描述了两例在接种新冠病毒mRNA疫苗后发生复发性心肌炎的病例,尽管之前有过一次发作且临床完全康复。在2021年9月至2022年9月期间,我们观察到两名男性青少年患有与新冠病毒mRNA疫苗相关的复发性心肌炎。在首次发作时,两名患者在接种第二剂BNT162b2 mRNA新冠病毒疫苗(Comirnaty®)几天后均出现发热和胸痛。血液检查显示心肌酶升高。此外,进行了完整的病毒检测,仅一例显示HHV7阳性。超声心动图显示左心室射血分数(LVEF)正常,但心脏磁共振扫描(CMR)结果符合心肌炎表现。他们接受了支持性治疗并完全康复。6个月的随访显示临床状况良好,心脏检查结果正常。CMR显示左心室壁有持续的病变及延迟强化(LGE)。几个月后,患者因发热、胸痛和心肌酶升高到急诊科就诊。未观察到LVEF降低。在第一例报告中,CMR显示有新的局灶性水肿区域,第二例则显示病变稳定。几天后他们心肌酶恢复正常,完全康复。这些病例报告强调了对接种新冠病毒mRNA疫苗后CMR结果符合心肌炎的患者进行严格随访的必要性。需要做出更多努力来描述新冠病毒疫苗接种后心肌炎的潜在机制,以了解复发风险和长期后遗症。